BD Respiratory Viral Panel Gets U.S. FDA Clearance
The FDA granted 510(k) clearance to BD's Respiratory Viral Panel for the BD MAX System, a diagnostic test that ID's respiratory viruses.
The FDA granted 510(k) clearance to BD's Respiratory Viral Panel for the BD MAX System, a diagnostic test that ID's respiratory viruses.
LightDeck Diagnostics received a $2 million contract for the development of a rapid, quantitative, multiplexed test for inflammatory markers.
The breath biomarker panel is intended to support research to distinguish between chronic inflammatory airway diseases including asthma, COPD, and IPF.
The panel tests nasopharyngeal swabs for the most common respiratory viruses and bacteria.
Read MoreThe test enables highly automated screening for latent tuberculosis.
Read MoreThe Headstart system is designed for home monitoring and integrates a simple, easy-to-use diagnostic with a reader and mobile phone app to capture patient-specific health data.
Read MoreIGeneX’s new BCA assays are simple and cost-effective tests that give either a positive or negative result for exposure to Borrelia spp.
Read MoreThe company will receive funding to provide the breath biopsy component of a research initiative designed to provide new insights into the mechanisms of response and nonresponse to treatment for seven immune-mediated diseases.
Read MorePositive and negative controls are designed to help laboratories deliver reliable MTB-RIF testing results.
Read MoreThe funding will enable Lophius to expand clinical performance data and finalize design of the assay for use on automated platforms.
Read MoreA study by Karolinska Institute researchers shows that an algorithm used in a mobile phone app can efficiently manage uncontrolled asthma.
Read MoreStudy subjects with uncontrolled asthma had substantially higher levels of local IL-26 in their airways, when compared with subjects with controlled asthma.
Read MoreAccess to innovative diagnostic solutions will contribute to the World Health Organization’s infectious disease elimination goals.
Read MoreThe panel is the first offering in a deep and broad pipeline of assays planned for QIAstat-Dx in the United States.
Read MoreThe study will collect breath samples from asthmatic patients and healthy controls to analyze breath-based biomarkers.
Read MoreThe BD Max MDR-TB panel has obtained the CE mark, supporting market launch in Europe.
Read MoreThe test uses genetic biomarkers to determine with high accuracy whether inhaled substances and chemicals that come into contact with the lungs are allergenic or not.
Read MoreAs soon as a baby is born, its immune system starts to change dramatically in response to the bacteria and viruses in its new environment. The study was made possible using new techniques of immune cell analysis.
Read More